Abbott Beats Q1 Profit and Revenue Estimates, But Cuts 2026 Outlook After $23B Exact Sciences Deal

Abbott beat Q1 earnings, boosted by cancer diagnostics deal, but cut 2026 profit outlook due to acquisition costs.